Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT

Rohtesh S. Mehta,Shernan G. Holtan,Tao Wang,Michael T. Hemmer,Stephen R. Spellman,Mukta Arora,Daniel R. Couriel,Amin M. Alousi,Joseph Pidala,Hisham Abdel-Azim,Vaibhav Agrawal,Ibrahim Ahmed,A. Samer Al-Homsi,Mahmoud Aljurf,Joseph H. Antin,Medhat Askar,Jeffery J. Auletta,Vijaya Raj Bhatt,Lynette Chee,Saurabh Chhabra,Andrew Daly,Zachariah DeFilipp,James Gajewski,Robert Peter Gale,Usama Gergis,Peiman Hematti,Gerhard C. Hildebrandt,William J. Hogan,Yoshihiro Inamoto,Rodrigo Martino,Navneet S. Majhail,David I. Marks,Taiga Nishihori,Richard F. Olsson,Attaphol Pawarode,Miguel Angel Diaz,Tim Prestidge,Hemalatha G. Rangarajan,Olle Ringdén,Ayman Saad,Bipin N. Savani,Hélène Schoemans,Sachiko Seo,Kirk R. Schultz,Melhem Solh,Thomas R. Spitzer,Jan Storek,Takanori Teshima,Leo F. Verdonck,Baldeep Wirk,Jean Yared,Jean-Yves Cahn,Daniel J. Weisdorf

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT

2020

PURPOSEThere is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for...

Keywords:

CRFS
Umbilical cord
Oncology
Internal medicine
Pathology
Medicine
alternative donor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations